Freenome fell 20.0% from $13.01 to $10.41, behind the S&P 500's +0.8%. Its worst day was Oct 12 (−16.2%), and its low came Jul 30 at $9.99.
Story events cover the past 12 months · Times ET
Jul 21, 2026 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Freenome closed at its lowest level of the year, 23.2% below where the year started.
−0.7% · S&P 500 +1.7%
Freenome shares rose 12.5%, while the S&P 500 fell 0.5%.
+12.5%, the year's best day · S&P 500 −0.5%
Freenome closed at its highest level of the year, 31.5% above where the year started.
+5.0%, on 6M shares, the year's heaviest volume · S&P 500 +0.1%
Freenome shares fell 16.2%, while the S&P 500 fell 0.1%.
−16.2%, the year's worst day · S&P 500 −0.1%
– Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw –– In an independent cohort, SimpleScreen Lung showed 85% sensitivity at 50% specificity and
+11.9% · S&P 500 +0.3%
EPS of $1.10 beat the $-0.20 estimate on $183.5M revenue (est. $84.9M); FY revenue guidance of $192.0M–$194.0M against the $102.4M consensus.
+7.3% · S&P 500 +1.3%
Where it ended: a close of $10.41 on Nov 13, 2026. Up next: Q4 2026 earnings on Feb 27, 2027 (EPS est. $0.09, revenue est. $84.9M).
Nothing in the past 12 months.
All FRNM dividend history